NCT05086107View on ClinicalTrials.gov

Pharmacokinetics and Safety of BV100 Administered as Single Intravenous Infusion to Subjects With Renal Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

October 8, 2021

Primary Completion Date

May 30, 2022

Study Completion Date

January 16, 2023

Conditions
Renal Impairment
Interventions
DRUG

BV100

Rifabutin for infusion

Trial Locations (1)

H-3529

CRU Hungary Kft., Early Phase Unit, Miskolc

Sponsors

Lead Sponsor

BioVersys AG
All Listed Sponsors
collaborator

Clinical Research Units Hungary

OTHER

lead

BioVersys AG

INDUSTRY